Addex Therapeutics Ltd(ADXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADXN Addex Therapeutics Ltd

Closed 11-13 16:00:00 EST

4.06

-1.23

-23.25%

盘后3.76

-0.30-7.39%

19:58 EST

High5.00	Low3.75	Vol560.12K
Open4.75	D1 Closing5.29	Amplitude23.63%
Mkt Cap10.54M	Tradable Cap2.93M	Total Shares2.60M
T/O2.55M	T/O Rate77.64%	Tradable Shares721.40K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADXN","market":"US","secType":"STK","nameCN":"Addex Therapeutics Ltd","latestPrice":4.06,"timestamp":1794603600000,"preClose":5.29,"halted":0,"volume":560116,"hourTrading":{"tag":"盘后","latestPrice":3.76,"preClose":4.06,"latestTime":"19:58 EST","volume":13147,"amount":51178.0451,"timestamp":1794617928579,"change":-0.3,"changeRate":-0.073892,"amplitude":0.083744},"delay":0,"changeRate":-0.2325141776937619,"floatShares":721400,"shares":2597100,"eps":-8.664,"marketStatus":"Closed","change":-1.23,"latestTime":"11-13 16:00:00 EST","open":4.75,"high":5,"low":3.75,"amount":2554992.4348256,"amplitude":0.236295,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-8.664,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":5,"adr":0,"adrRate":120,"exchange":"NASDAQ","adjPreClose":5.29,"preHourTrading":{"tag":"盘前","latestPrice":4.75,"preClose":5.29,"latestTime":"09:29 EST","volume":80710,"amount":385301.30758,"timestamp":1794580199509,"change":-0.54,"changeRate":-0.102079,"amplitude":0.187146},"postHourTrading":{"tag":"盘后","latestPrice":3.76,"preClose":4.06,"latestTime":"19:58 EST","volume":13147,"amount":51178.0451,"timestamp":1794617928579,"change":-0.3,"changeRate":-0.073892,"amplitude":0.083744},"volumeRatio":0.100418},"requestUrl":"/m/hq/s/ADXN/wiki","defaultTab":"wiki","newsList":[{"id":"2683511668","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2683511668","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683511668?lang=en_us&edition=fundamental","pubTime":"2026-11-13 02:52","pubTimestamp":1794509577,"startTime":"0","endTime":"0","summary":"Addex Therapeutics  said late Wednesday its spin-out company Neurosterix closed a $105 million series B financing, valuing Addex's 8.5% stake at $18.6 million.Shares soared 64%, with intraday trading volume catapulting to over 20.0 million from a daily average of about 140,000.JX Luxventure  reported a 172% year-over-year surge in H1 revenue and a 75% jump in gross profit, showing that \"the strategic roadmap we set in motion in 2025 is actively working and scaling our business effectively.\"Shares climbed past 15%, with intraday trading volume rising to more than 27,000 from the stock's daily average of nearly 40,000.UBS adjusted its price target for Sight Sciences  to $13.50 from $8, while maintaining its buy rating.Shares rose 2.3%, hitting a 52-week high, with intraday trading volume at 262,000, versus a daily average of roughly 313,000.Price: 4.68, Change: +1.83, Percent Change: +63.96","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADXN.AU","BK7142","JXG","BK4082","BK4202","ADXN","BK4539","SGHT","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682590557","title":"NASDAQ Trade Halt Volatility Trading Pause at 09:47 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2682590557","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682590557?lang=en_us&edition=fundamental","pubTime":"2026-11-12 22:47","pubTimestamp":1794494841,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 09:47 AM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nAQN2MTCSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADXN","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682587476","title":"Press Release: Addex Spin-Out Neurosterix Closes $105 Million Series B Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2682587476","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682587476?lang=en_us&edition=fundamental","pubTime":"2026-11-12 05:32","pubTimestamp":1794432720,"startTime":"0","endTime":"0","summary":"Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, November 11, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","PAM","BK4081","NAM.AU","BK4007","ADXN","BK7064","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679342575","title":"Press Release: ADDEX Increases Issued SHARE Capital to Create Treasury Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2679342575","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679342575?lang=en_us&edition=fundamental","pubTime":"2026-10-29 14:00","pubTimestamp":1793253600,"startTime":"0","endTime":"0","summary":"Chief Executive Officer       Partner, Halsin Partners","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ADXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673028595","title":"Press Release: Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2673028595","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673028595?lang=en_us&edition=fundamental","pubTime":"2026-10-08 13:00","pubTimestamp":1791435600,"startTime":"0","endTime":"0","summary":"Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, October 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a por","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4563","ADXN","NTX","PAM","CSF","BK4139","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672079179","title":"Press Release: Addex Therapeutics Announces Executive Management Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2672079179","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672079179?lang=en_us&edition=fundamental","pubTime":"2026-10-02 13:00","pubTimestamp":1790917200,"startTime":"0","endTime":"0","summary":"-- Jean-Philippe Rocher Appointed Head of Pharmaceutical Development","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADXN","BK4539","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670256431","title":"NASDAQ Trade Halt Volatility Trading Pause at 11:24 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2670256431","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670256431?lang=en_us&edition=fundamental","pubTime":"2026-09-28 23:24","pubTimestamp":1790609080,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 11:24 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nAQN2ML8OP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ADXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670528572","title":"Press Release: Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2670528572","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670528572?lang=en_us&edition=fundamental","pubTime":"2026-09-28 13:00","pubTimestamp":1790571600,"startTime":"0","endTime":"0","summary":"-- Regained rights to GABAB positive allosteric modulator portfolio from. -- Spin-out company, Neurosterix continued to progress through Phase 1. clinical development with the M4 PAM candidate, NTX-253. -- Continued advancing GABAB PAM chronic cough candidate through preclinical. developmentKey H1 2026 Financial DataCHF' thousands             Q2 26    Q2 25   Change    H1 26    H1 25   Change","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4539","BK4007","ADXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669445945","title":"Press Release: Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669445945","media":"Dow Jones","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669445945?lang=en_us&edition=fundamental","pubTime":"2026-09-24 13:00","pubTimestamp":1790226000,"startTime":"0","endTime":"0","summary":"Geneva, Switzerland, September 24, 2026 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its 2026 Half-Year and Second Quarter financial results on September 28, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST  on September 28, 2026.Title:  Addex Therapeutics Reports 2026 Half-Year and Second Quarter Financial Results and Provides Corporate UpdateDate: September 28, 2026Time: 16:00 CET Joining the Conference Call:1. Participants are required to register in advance of the conference using. the link provided below. Upon registering, each participant will be. provided with Participant Dial-in numbers, and a unique Personal PIN.use the conference acces","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADXN","LENZ","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662762406","title":"Press Release: ADDEX Raises USD 2.8 Million Through Its ATM Agreement and Extends Cash Runway to the Fourth Quarter 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2662762406","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662762406?lang=en_us&edition=fundamental","pubTime":"2026-08-26 13:00","pubTimestamp":1787720400,"startTime":"0","endTime":"0","summary":"Chief Executive Officer       Partner, Halsin Partners","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CROC","EUFX","BK4139","ADXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661523114","title":"NASDAQ Trade Halt Volatility Trading Pause at 02:50 Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2661523114","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661523114?lang=en_us&edition=fundamental","pubTime":"2026-08-21 02:50","pubTimestamp":1787251831,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 02:50 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nAQN2MFXNA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADXN","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649647109","title":"Addex Therapeutics announces publication of new ADX71743 preclinical research","url":"https://stock-news.laohu8.com/highlight/detail?id=2649647109","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649647109?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:15","pubTimestamp":1783502113,"startTime":"0","endTime":"0","summary":"Addex Therapeutics (ADXN) announced publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/addex-therapeutics-announces-publication-of-new-adx71743-preclinical-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/addex-therapeutics-announces-publication-of-new-adx71743-preclinical-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADXN","BK4007","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649957215","title":"Press Release: Addex Announces Publication of Research Highlighting Therapeutic Potential of Mglu7 Modulation in Regulating Sleep and Wakefulness","url":"https://stock-news.laohu8.com/highlight/detail?id=2649957215","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649957215?lang=en_us&edition=fundamental","pubTime":"2026-07-08 13:00","pubTimestamp":1783486800,"startTime":"0","endTime":"0","summary":"Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, July 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADXN","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647658440","title":"Press Release: Addex Shareholders Approve All Resolutions at Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2647658440","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647658440?lang=en_us&edition=fundamental","pubTime":"2026-06-30 13:00","pubTimestamp":1782795600,"startTime":"0","endTime":"0","summary":"Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, June 30, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4195","ADXN","AGM","BK4139","BK4229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646694821","title":"Addex Therapeutics Reports Q1 2026 Net Loss Of CHF 1.71M Versus CHF 1.47M A Year Ago, Cash CHF 0.9M","url":"https://stock-news.laohu8.com/highlight/detail?id=2646694821","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646694821?lang=en_us&edition=fundamental","pubTime":"2026-06-25 13:41","pubTimestamp":1782366064,"startTime":"0","endTime":"0","summary":"Basic and diluted loss per share remained stable at CHF 0.01 per share for the three-month periods ended March 31, 2026 and 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/06/60088935/addex-therapeutics-reports-q1-2026-net-loss-chf-1-71m-versus-chf-1-47m-year-ago-cash-chf-0-9m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADXN","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646829973","title":"Press Release: Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2646829973","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646829973?lang=en_us&edition=fundamental","pubTime":"2026-06-25 13:00","pubTimestamp":1782363600,"startTime":"0","endTime":"0","summary":"Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, June 25, 2026 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2026 financial results and provided a corporate update.\"Our spin-out, Neurosterix, made great progress during the quarter and are on track to complete the Phase 1 study with NTX-253, an M4 positive allosteric modulator with potential in schizophrenia, in July,\" said Tim Dyer, CEO of Addex. \"We look forward to seeing the data from the study when available later in the summer.\"Operating Highlights:-- Spin-out Neurosterix continued to progress through Phase 1 clinical. developmentKey Q1 2026 Financial DataCHF' thousands                     Q1 26    Q1 25   Change","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4539","BK4007","ADXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645204532","title":"Press Release: Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645204532","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645204532?lang=en_us&edition=fundamental","pubTime":"2026-06-22 13:00","pubTimestamp":1782104400,"startTime":"0","endTime":"0","summary":"Geneva, Switzerland, June 22, 2026 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its First Quarter 2026 Financial Results on June 25, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST  on June 25, 2026.Title:  Addex Therapeutics Reports Q1 2026 Financial Results and Provides Corporate Update. the link provided below. Upon registering, each participant will be","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ADXN","BK4139","BK4007","BK4218","BK4585","BK4588","HST","BK4181","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641582192","title":"Press Release: Addex Convenes Annual General Meeting 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2641582192","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641582192?lang=en_us&edition=fundamental","pubTime":"2026-06-05 13:00","pubTimestamp":1780635600,"startTime":"0","endTime":"0","summary":"Geneva, Switzerland, June 5, 2026 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its 2026 Annual General Meeting will take place on Monday June 29, 2026 at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva .Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant , is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in sub","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ADXN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.addextherapeutics.com","stockEarnings":[{"period":"1week","weight":0.8241},{"period":"1month","weight":0.7575},{"period":"3month","weight":-0.1109},{"period":"6month","weight":-0.2232},{"period":"1year","weight":-0.3995},{"period":"ytd","weight":-0.3148}],"compareEarnings":[{"period":"1week","weight":0.0329},{"period":"1month","weight":-0.0269},{"period":"3month","weight":-0.0248},{"period":"6month","weight":0.0243},{"period":"1year","weight":0.1079},{"period":"ytd","weight":0.1103}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.20245},{"month":2,"riseRate":0.285714,"avgChangeRate":0.091856},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.134039},{"month":4,"riseRate":0.571429,"avgChangeRate":-0.057535},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.045257},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.098028},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.006493},{"month":8,"riseRate":0.285714,"avgChangeRate":0.058829},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.127045},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.0376},{"month":11,"riseRate":0.142857,"avgChangeRate":0.001543},{"month":12,"riseRate":0.5,"avgChangeRate":-0.002424}],"exchange":"NASDAQ","name":"Addex Therapeutics Ltd","nameEN":"Addex Therapeutics Ltd","securityTypeName":"DR","adrRate":"1:120"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Addex Therapeutics Ltd(ADXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Addex Therapeutics Ltd(ADXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Addex Therapeutics Ltd,ADXN,Addex Therapeutics Ltd股票,Addex Therapeutics Ltd股票老虎,Addex Therapeutics Ltd股票老虎国际,Addex Therapeutics Ltd行情,Addex Therapeutics Ltd股票行情,Addex Therapeutics Ltd股价,Addex Therapeutics Ltd股市,Addex Therapeutics Ltd股票价格,Addex Therapeutics Ltd股票交易,Addex Therapeutics Ltd股票购买,Addex Therapeutics Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Addex Therapeutics Ltd(ADXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Addex Therapeutics Ltd(ADXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction